Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 1, 1996, Pages 277-283

  Balena, Raffaella ^a   Markatos, Angelo ^a   Seedor, J Gregory ^a   Gentile, Michael ^a   Stark, Christopher ^a   Peter, C P ^a   Rodan, Gideon A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; FEMALE; LONG TERM CARE; LUMBAR VERTEBRA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOID; OSTEOPOROSIS; PRIORITY JOURNAL;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE DEVELOPMENT; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; DOGS; FEMALE; LUMBAR VERTEBRAE; MALE; TIME FACTORS;

EID: 0029875341     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ADAMSON, B. P., GALLACHER, S. J., BYARS, J , RALSTON, S. H., BOYLE, I. T. AND BOYCE, B. F.: Mineralization defects with pamidronate therapy for Paget's Disease. Lancet 342: 1459-1460, 1993.
2. ATTIE, M. F.: Bisphosphonate therapy for osteoporosis. Hosp. Pract. 26: 87-90, 1991.
3. AVERBUCH, S. D.: New bisphosphonates in the treatment of bone metastases Cancer (Philadelphia) 72: 3443-3452, 1993.
4. AVIOLI, L V.: Therapy with bisphosphonates, sodium fluoride, thiazides, and vitamin D metabolites. In The Osteoporotic Syndrome: Detection, Prevention, and Treatment, ed. by L. V. Avioli, pp. 155-169, Wiley-Liss, Inc , New York, 1993.
5. AXELROD, D. W. AND TEITELBAUM, S. L.: Results of long-term cyclical etidronate therapy: Bone histomorphometry and clinical correlates. J. Biomed. Mater. Res. 9: (Suppl. 1) S-136, 1994.
6. BALENA, R , TOOLAN, B. C., SHEA, M., MARKATOS, A., MEYERS, E. R., LEE, S. D , OPAS, E. E., SEEDOR, J. G., KLEIN, H., FRANKENFIELD, D , QUARTUCCIO, H., FIORAVANTI, C., CLAIR, J., BROWN, E., HAYES, W. C. AND RODAN, G. A.: The effects of two year treatment with the aminobisphosphonate ALN on bone metabolism, bone histomorphometry and bone strength in ovariectomized non-human primates. J. Clin. Invest. 92: 2677-2686, 1993.
7. BARON, R., VIGNERY, A., NEFF, L., SILVERGLATE, A. AND SANTA MARIA, A.: Processing of undecalcified bone specimens for bone histomorphometry. In Bone Histomorphometry: Techniques and Interpretation, ed. by R. R. Recker, pp. 13-35, CRC Press, Boca Raton, 1983.
8. BINGHAM, C. T. AND FITZPATRICK, L. A.: Non-invasive testing in the diagnosis of osteomalacia. Am. J. Med. 95: 519-523, 1993.
9. BOYCE, B. F., ADAMSON, B. B., GALLACHER, S. J., BYARS J., RALSTON S. H. AND BOYLE I. T.: Mineralization defects after pamidronate for Paget's Disease Lancet 343: 1231-1232, 1994.
10. COMPSTON, J. E.: HRT and osteoporosis. Br. Med. Bull. 48: 309-344, 1992.
11. ETTINGER, B.: Use of low-dosage 17β-estradiol for the prevention of osteoporosis. Clin. Ther. 15: 950-962, 1993.
12. FLEISCH, H.: Bisphonates in Bone Disease-From the Laboratory to the Patient, Stampfli & Co., Ltd., Berne, 1993.
13. FLORA, L., HASSING, G. S., CLOYD, G. G., SEVAN, J. A , PARFITT, A. M. AND VILLANUEVA, A. R.: The long-term skeletal effects of EHDP in dogs. Metab. Bone Dis. & Rel. Res. 3: 289-300, 1981.
14. FLORA, L., HASSING, G. S., PARFITT, A. M. AND VILLANUEVA, A. R.. Comparative skeletal effects of two diphosphonates in dogs. Metab. Bone Dis. & Rel. Res. 2: 389-407, 1980.
15. FROST, H. M.: Some ABC's of skeletal pathophysiology. 5. Microdamage physiology. Calcif. Tissue. Int. 49: 229-231, 1991.
16. GUY, J. A., SHEA, M., PETER, C. P., MORRISEY, R. AND HAYES, W. C.: Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int. 53: 283-288, 1993.
17. KELLY, P. J. AND EISMAN, J. A.: Osteoporosis: Genetic effects on bone turnover and bone density. Ann. Med. 25: 99-101, 1994.
18. KIMMEL, D. B. AND JEE, W. S. S.: A quantitative histologic study of bone turnover in young adult beagles. Anat. Rec. 203: 31-45, 1982.
19. LAFAGE, M. H., BALENA, R., BATTLE, M. A., SHEA, M., SEEDOR, J. G., KLEIN, H., HAYES, W. C. AND RODAN, G. A.: Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs: A one-year study. J. Clin. Invest. 95: 2127-2133, 1995.
20. LIN, J. H., DUGGAN, D. E., CHEN, I. W. AND ELLWORTH, R. L.: Physiological disposition of alendronate a potent bisphoshonate in laboratory animals. Drug Metab. Dispos 19: 926-932, 1991.
21. LINDSAY, R., COSMAN, F. AND NIEVES, J.: Estrogen. Effect and actions in osteoporosis. Osteoporosis Int. 3: (Suppl. 1) 150-153, 1993.
22. OTT, S. M., WOODSON, G. C., HUFFER, W. E., MILLER, P. D AND WATTS, N B.: Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis J. Clin. Endocrinol. Metab. 78: 968-972, 1994.
23. PAPAPOULOS, S.: The role of bisphosphonates in the prevention and treatment of osteoporosis. Am. J. Med. 95: 48-52, 1993.
24. PARFITT, A. M.: The physiological and chemical significance of bone histomorphometric data. In Bone Histomorphometry. Techniques and Interpretations ed. by R. Recker, pp. 143-223, CRC Press, Inc., Boca Raton, 1983.
25. PARFITT, A M.: Bone forming cells in clinical conditions. In Bone, A Treatise, Vol 1, The Osteoblast and Osteocyte, ed. by B K. Hall, pp. 359-429, The Telford Press, Caldwell, 1990.
26. PARFITT, A. M.: Use of bisphosphonates in the prevention of bone loss and fractures. Am. J. Med. 91: 5B-42S-5B-46S, 1991.
27. PARFITT, A. M.: Pathophysiology of bone fragility. In Osteoporosis Proceedings Fourth International Symposium on Osteoporosis and Consensus Development Conference, ed. by C. Christiansen and B. Riis, pp. 164-166, Handelstrykkeriet Aalborg ApS, Aalborg, 1993.
28. PARFITT, A. M.: Osteonal and hemi-osteonal remodeling. The spatial and temporal framework for signal traffic in adult human bone. J Cell. Biochem. 55: 273-286, 1994.
29. PARFITT, A. M., DREZNER, M. K., GLORIEUX, F. H., KANIS, J. A., MALLUCHE, H., MEUNIER, P. J., OTT, S. M. AND RECKER, R. R.: Bone histomorphometry: Standardization of nomenclature, symbols and units. Report of the ASBMR histomorphometry nomenclature committee. J. Bone Miner. Res. 2: 595-610, 1987.
30. PARFITT, A. M., MATTEWS, C. H. E., VILLANUEVA, A. R., KLEEREKOPER, M., FRAME, B. AND RAO, D. S.: Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the micro anatomic and cellular mechanisms of bone loss J. Clin. Invest. 72: 1396-1409, 1983.
31. PETER, C. P., COOK, W. O., NUNAMAKER, D. M., PROVOST, M. T., SEEDOR, J. G. AND RODAN, G. A.: Effect of alendronate on fracture healing and bone remodeling in dogs. J. Orthop. Res., in press, 1995.
32. PETER, C. P., GUY, J., SHEA, M., BAGDON, W., KLINE, W. F. AND HAYES, W. C : Long-term safety of the Aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone. J. Pharmacol. Exp. Ther. 276: 271-276, 1996.
33. REID, I. R., CUNDY, T., IBBERTSON, H. K. AND KING, A. R.: Osteomalacia after pamidronate for Paget's disease. Lancet 343: 855, 1994.
34. RIGGS, B. L., MELTON, L. J. III AND O'FALLON, W. M.: Toward optimal therapy of established osteoporosis: Evidence that antiresorptive and formation-stimulating regimens decrease vertebral fracture rate by independent mechanisms. In Osteoporosis Proceedings: Fourth International Symposium on Osteoporosis and Consensus Development Conference, ed by C. Christiansen and B. Riis, pp. 13-15, Handelstrykkeriet Aalborg ApS, Aalborg, Denmark, 1993.
35. RODAN, G. A.: Mechanical loading, estrogen deficiency, and the coupling of bone formation to resorption. J. Bone Miner. Res. 6: 527-530, 1991.
36. RODAN, G. A. AND BALENA, R.: Bisphosphonates in the treatment of metabolic bone diseases. Ann. Med. 25: 373-378, 1993.
37. RODAN, G. A., SEEDOR, J. G. AND BALENA, R.: Preclinical pharmacology of alendronate. Osteopor. Int. 2: S5-S10, 1993.
38. SEEDOR, J. G., QUARTUCCIO, H. A. AND THOMPSON, D. D.: The bisphosphonate alendronate (ALN) inhibited bone loss due to ovariectomy in rats. J. Bone Miner Res 6: 339-346, 1991.
39. SHEN, V , DEMPSTER, D. W., BIRCHMAN, R., MELLISH, R. W., CHURCH, E., KOHN, D. AND LINDSAY R.: Lack of changes in histomorphometric, bone mass, and biochemical parameters in ovariohysterectomized dogs. Bone 13: 311-316, 1992.
40. STORM, T., STEINICHE, T., THAMSBORG, G. AND MELSEN, F.: Changes in histomorphometry after long term treatment with intermittent cyclical etidronate for postmenopausal osteoporosis. J. Bone Miner. Res. 8: 199-208, 1993.
41. THOMPSON, D. D., SEEDOR, J G., WEINREB, M., ROSINI, S. AND RODAN, G. A.: Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization. J. Bone Miner Res. 5: 279-286, 1990.
42. TOOLAN, B. C., SHEA, M., MEYERS, E. R., BORCHERS, R. E., SEEDOR, J. G., QUARTOCCIO, H., RODAN, G. AND HAYES, W. C.: Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J. Bone Miner. Res. 7: 1399-1406, 1992.
43. YAMAMOTO, M., MARKATOS, A., SEEDOR, J G., MASARACHIA, P., GENTILE, M., RODAN, G. A. AND BALENA, R : The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats. Calcif. Tissue Int. 53: 278-282, 1993.